EP PerMed

The European Partnership for Personalised Medicine

The European Partnership for Personalised Medicine (EP PerMed) aims to improve future healthcare for all citizens through personalised therapy, diagnosis and prevention. With a total budget of around €375 million, provided by the EU and more than 50 international partners, EP PerMed will not only significantly support the transnational development of personalised medicine approaches over the next ten years, but also their successful translation into clinical practice. The announcement for the first joint transnational call for proposals has now been published.

While the final EP PerMed website is still under development, you will find preliminary information about the Partnership here. Stay tuned and subscribe to our EP PerMed newsletter to receive all updates on the project and calls. You may also follow EP PerMed on LinkedIn or X (Twitter).

For questions around EP PerMed, please contact the EP PerMed Coordination Unit: eppermed@dlr.de

About EP PerMed

The vision of the European Partnership for Personalised Medicine (EP PerMed) is to improve health outcomes within sustainable healthcare systems through research, development, innovation and implementation of personalised medicine approaches for the benefit of patients, citizens, and society.

Within EP PerMed, several earlier European Initiatives are joined under one roof. It will continue the activities of ERA PerMed in funding transnational innovation and research projects. In addition, EP PerMed will work closely together with ICPerMed for overarching strategic activities.

EP PerMed builds on over 15 years of EU-funded consortia, initiatives & events, but also on a wide range national/regional activities and efforts in all areas of the personalised medicine value continuum.

Key figures of EP PerMed:

  • Duration: 10 years
  • Total budget (national / regional funding plus EC contribution): Approximately 370 Mio. Euro
  • Partners: More than 50, mainly funding organisations from Europe and beyond

Newsletter

In addition to funding personalised medicine research, EP PerMed will:

  • Act as global personalised medicine platform for scientific and strategic dialogue and alignment.
  • Facilitate and accelerate all steps of implementation through the full value continuum, so that personalised medicine achievements can be successfully implemented.
  • Foster demonstration projects and promote successes and lessons learned to demonstrate evidence of personalised medicine implementation.

The Strategic Research and Innovation Agenda for Personalised Medicine (SRIA for PM, 2023), developed by EP PerMed partners, is the basis for the partnership’s structure and a wide range of its activities.

All steps of the SRIA development and the proposal preparation were strongly supported by numerous PM-experts, stakeholders and the European Commission (EC). The partnership builds on several developments, initiatives and projects such as ERA PerMed, ICPerMed and its supporting projects (ICPerMed Family) funded by the EC. The EP PerMed consortium will bring together most of the partners from these initiatives and expand its scope with additional partners from Europe and beyond.

An overview of the PM 'value continuum' or 'system of health', integrating research, innovation and implementation aspects from the SRIA for PM. Results from one sector should feed into the next step, but also give feedback to previous steps in the value chain, forming a cycle of knowledge and insights that flows in both directions. EP PerMed’s activities aim to support all aspects, key players and elements in this circle.
An overview of the PM ‘value continuum’ or ‘system of health’, integrating research, innovation and implementation aspects from the Strategic Research & Innovation Agenda for Personalised Medicine. Results from one sector should feed into the next step, but also give feedback to previous steps in the value chain, forming a cycle of knowledge and insights that flows in both directions. EP PerMed’s activities aim to support all aspects, key players and elements in this circle.
© DLR. All rights reserved

Related Initiatives

Several European Initiatives in personalised medicine contributed to the development of EP PerMed:

The International Consortium for Personlised Medicine (ICPerMed)

Logo of the International Consortium of Personalised MEdicine

ICPerMed provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation. The high level of participation from all over Europe and beyond enables ICPerMed to efficiently map the scientific and political landscape. This allows an alignment of research and funding activities on European and later international level.

www.icpermed.eu

The ERA-Net for Personalised Medicine (ERA PerMed)

ERA PerMed is an ERA-Net Cofund, supported by 32 partners from 23 countries and cofunded by the European Commission. The national and regional funding organisations active in ERA PerMed have launched five Joint Transnational Calls for collaborative innovative research projects in Personalised Medicine (PM).

https://eppermed.isciii.es

ICPerMed Family

Several coordination and support actions were started in support of ICPerMed. Their experiences and results were also crucial for the preparation of EP PerMed, and many of their activities will be continued within EP PerMed.

www.icpermed.eu/en/related-initiatives.php

Steps towards EP PerMed

The development of the European Partnership for Personalised Medicine has a long history, starting in early 2021 with the publication of a first draft concept for the Partnership. Several steps followed, such as an ICPerMed workshop to support EP PerMed, an online consultation and the publication of a draft proposal and SRIA for PM, coordinated by ICPerMed and the EP PerMed Drafting Group. More information on the EP PerMed development process is available on the ICPerMed website.

Background: European Partnerships

European Partnerships are a “new generation” of partnerships that will in Horizon Europe replace previous forms of partnerships, e.g. ERA-Nets or JPIs. Their general aim is to bring the European Commission and private and/or public partners together to address some of Europe’s most pressing challenges through concerted research and innovation initiatives. They are a key implementation tool of Horizon Europe, and contribute significantly to achieving the EU’s political priorities.